StockNews.com Upgrades Abeona Therapeutics (NASDAQ:ABEO) to Hold

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) was upgraded by research analysts at StockNews.com from a "sell" rating to a "hold" rating in a research note issued on Friday.

A number of other brokerages also recently issued reports on ABEO. Cantor Fitzgerald reiterated an "overweight" rating and issued a $18.00 price target on shares of Abeona Therapeutics in a report on Tuesday, October 29th. HC Wainwright reaffirmed a "buy" rating and issued a $15.00 target price on shares of Abeona Therapeutics in a report on Monday, November 25th.

Abeona Therapeutics Price Performance

ABEO traded up $0.07 during trading on Friday, reaching $5.70. 210,374 shares of the company traded hands, compared to its average volume of 415,259. The company has a market cap of $247.78 million, a P/E ratio of -2.12 and a beta of 1.44. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. Abeona Therapeutics has a 12-month low of $3.05 and a 12-month high of $9.01. The firm has a fifty day simple moving average of $6.18 and a 200 day simple moving average of $5.51.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its holdings in Abeona Therapeutics by 21.7% during the third quarter. Geode Capital Management LLC now owns 465,317 shares of the biopharmaceutical company's stock worth $2,942,000 after buying an additional 83,050 shares during the period. XTX Topco Ltd bought a new position in shares of Abeona Therapeutics in the 3rd quarter worth $160,000. Jane Street Group LLC purchased a new stake in shares of Abeona Therapeutics during the 3rd quarter worth $84,000. Western Standard LLC boosted its position in Abeona Therapeutics by 7.0% during the third quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company's stock valued at $10,732,000 after purchasing an additional 110,998 shares in the last quarter. Finally, Citigroup Inc. grew its stake in Abeona Therapeutics by 10.1% in the third quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company's stock valued at $3,897,000 after purchasing an additional 56,332 shares during the last quarter. 80.56% of the stock is currently owned by institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.